Abstract: The present invention relates to a phase shifter comprising: an operation unit connected to a plurality of phase transformation units to synchronize respective phases changed through the plurality of phase transformation units; a driving unit having a motor with a rotary shaft, a plurality of gears rotating interlinked with the rotary shaft, and a screw connected to any one of the plurality of gears to transmit power to the operation unit, the driving unit driving the operating unit through the motor, the plurality of gears, and the screw, wherein the screw is seated on a seating portion provided on an outer side of the motor, and pivotally rotates on the seating portion.

Abstract: The present invention relates to a phase conversion unit comprising: a first circuit board having a plurality of first circuit patterns; a plurality of second circuit boards each having a second circuit pattern, a partial area of which overlaps and is connected to one among the plurality of the first circuit patterns; a plurality of movement members for pressing the plurality of second circuit boards toward the first circuit board, moving the second circuit boards in a first direction to change the length by which the first circuit patterns and the second circuit pattern overlap each other, and thereby converting a phase through the changed length; and a housing disposed on the first circuit board and receiving the plurality of second circuit boards and the plurality of movement members.

Abstract: A pharmaceutical composition for preventing or treating female climacteric syndromes comprising Loganin which increases the concentration of estradiol (17?-estradiol, E2) in the blood of a menopausal mouse model and has shown efficacies such as an increase in the estrogen receptor alpha expression in the uterus, which remedies uterine contraction and degeneration, and decreases in the accumulation and the size of adipocytes in liver and the abdominal adipose tissues and the liver and weight loss, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.

Abstract: A pharmaceutical composition for preventing or treating female climacteric syndromes comprising Loganin which increases the concentration of estradiol (17?-estradiol, E2) in the blood of a menopausal mouse model and has shown efficacies such as an increase in the estrogen receptor alpha expression in the uterus, which remedies uterine contraction and degeneration, and decreases in the accumulation and the size of adipocytes in liver and the abdominal adipose tissues and the liver and weight loss, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.